The AIM with Immunotherapy Initiative – Home › Forums › Immunotherapy › Expectations for therapy › nivolumab › Reply To: nivolumab
The prescribing information indicates until disease progression or unacceptable toxicity. The interpretation of these criteria varies from institution to institution and from provider to provider
